![](https://investorshub.advfn.com/uicon/664465.png?cb=1588091362)
Monday, September 30, 2019 11:48:48 AM
https://www.linkedin.com/company/neurosense-therapeutics/
Scroll down----> https://www.neurosense-tx.com/team
She doesn't even mention OWCP..
Dr. Oron Yacoby-Zeevi
Chief Scientific Officer
Chief Scientific Officer responsible for pre-clinical studies, formulation development and company’s pipeline.
Prior to working at NeuroSense, Oron was CSO at NeuroDerm, responsible for the development of their unique formulation.
In the past, she also served as Chief Science Officer at Harlan Biotech Israel Ltd., and R&D team leader at Insight Biopharmaceuticals Ltd.
She has 20 years experience in leading research and development programs, and GLP compliant pre-clinical development of numerous small molecule drugs and biologics, in various indications, including CNS diseases.
She is the author of more than 15 patents.
DVM; The Hebrew University of Jerusalem. PhD in Microbiology and Immunology; Ben-Gurion University
OWCP is not a going concern in her life any longer...it appears it never was....
Except for the pr announcing her appointment as CSO...
Where is that noted on LinkedIN..while everything else she's done or is doing now is...
Coincidence?
Nope.
Whoever is careless with the truth in small matters cannot be trusted with important matters.
– Albert Einstein
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM